Oric Pharmaceuticals Highlights 2025 Milestones, Plans Phase 3 Prostate Trial

Biotech firm outlines development priorities for lead oncology programs, including plans to start Phase 3 study for prostate cancer in first half of 2025.

Published on Feb. 14, 2026

Got story updates? Submit your updates here. ›

Oric Pharmaceuticals used a recent biotech conference to outline its development priorities for two lead oncology programs and reiterate expected milestones for 2025, including plans to initiate a Phase 3 study in prostate cancer in the first half of the year. The company highlighted data on its PRC2 inhibitor rinzimetostat and its EGFR-targeted therapy enozertinib, and discussed market sizing and combination strategies.

Why it matters

Oric's pipeline of small molecule therapies aimed at overcoming cancer resistance mechanisms represents an important area of oncology research, as many patients develop resistance to standard treatments. The company's plans for late-stage trials in prostate and lung cancer could lead to new treatment options for patients with limited options.

The details

Oric discussed data on its PRC2 inhibitor rinzimetostat, including early proof-of-concept results showing PSA50 and PSA90 responses, as well as a more favorable safety profile compared to Pfizer's competing PRC2 inhibitor. The company plans to provide an 'early look' at data from 20-25 patients in Q1 2025 to inform its planned Phase 3 study. For its EGFR-targeted therapy enozertinib, Oric highlighted competitive systemic response rates and differentiated central nervous system activity, with plans for three additional readouts in the second half of 2025. Oric also discussed market sizing for the EGFR exon 20 and PACC mutation patient populations.

  • Oric plans to initiate a Phase 3 study for rinzimetostat in the first half of 2025.
  • Oric expects to have data from the rinzimetostat Phase 3 study in the second half of 2027.

The players

Oric Pharmaceuticals

A clinical-stage biopharmaceutical company headquartered in South San Francisco, California, dedicated to discovering and developing small molecule therapeutics to overcome resistance mechanisms in solid tumor oncology.

Matt Panuwat

Chief Business Officer of Oric Pharmaceuticals.

Dominic Piscitelli

Chief Financial Officer of Oric Pharmaceuticals.

Pfizer

A pharmaceutical company with a competing PRC2 inhibitor program.

J&J

A pharmaceutical company that may provide a clinical supply agreement for an androgen receptor inhibitor to be used in Oric's rinzimetostat Phase 3 combination study.

Bayer

A pharmaceutical company that may provide a clinical supply agreement for an androgen receptor inhibitor to be used in Oric's rinzimetostat Phase 3 combination study.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.